regulator of G protein signaling 5Genealiases: MST092 · MST106 · MST129 · MSTP032 · MSTP092 · MSTP106
Q-omics provides the consensus-scored RGS5 profile across patient tissues and cancer cell-line models. RGS5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RGS5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RGS5 RNA expression shows 18,405 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where RGS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS5 survival associations across molecular data types. RGS5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS5 RNA expression–survival associations across cancer types. High RGS5 expression shows unfavorable associations in KIRP and UVM, but favorable associations in HNSC, KIRC, THCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RGS5 RNA expression.
This table summarizes RGS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RGS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS5 shows lower tumor expression in BLCA, LUSC, LUAD and KICH and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher RGS5 RNA expression in tumor versus normal tissue (log2 FC = +2.837, t-test p < 0.001).
This table shows molecular features associated with RGS5 in patient tissues and cancer cell lines. In patient samples, RGS5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
